Why Moderna, Inc. (MRNA) Stock Rose 14.2% on Oct 9, 2026
What happened
Moderna surged +11.51% to $219.68, driven by two catalysts: an exclusive report (New York Times, per web sources) detailing a major national public-private partnership to accelerate mRNA cancer vaccine development, and the company's official reinclusion in the Nasdaq-100 Index effective today. Volume traded 2.15x the historical average for this time of day, signaling broad institutional participation.
Moderna earnings on 2026-11-05 (consensus EPS estimate: −$1.10); official details and timeline confirmation for the NIH cancer vaccine partnership at its December launch.
Other developments that session
Moderna shares surged 11% alongside broader biotech sector rally led by vaccine stocks.
Frequently asked questions
Why did Moderna, Inc. (MRNA) stock rise on Oct 9, 2026?
Moderna surged +11.51% to $219.68, driven by two catalysts: an exclusive report (New York Times, per web sources) detailing a major national public-private partnership to accelerate mRNA cancer vaccine development, and the company's official reinclusion in the Nasdaq-100 Index effective today. Volume traded 2.15x the historical average for this time of day, signaling broad institutional participation.
How much did MRNA stock rise on Oct 9, 2026?
MRNA rose 14.2% during the Oct 9, 2026 trading session.